Do I need more therapy after prostate cancer surgery?

The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your care.

Contact the GenomeDx Patient Care Team at 1.888.792.1601 (toll-free) or e-mail client.services@genomedx.com
Decipher® is a unique genomic test that assesses your prostate cancer to help you and your doctor personalize your postoperative care.

Understanding your risk

After surgery, many men will be cured but some will have clinical risk factors that indicate they are at risk for their cancer returning.*

In reality, only about 5% of clinically high risk men will experience disease recurrence within 5 years of surgery.¹

New advances in genomic testing have made it possible to more accurately determine your risk after surgery.

* According to clinical practice guidelines, men with extra-prostatic disease, seminal vesicle invasion, positive surgical margins or rising PSA are at higher risk of their disease returning.
Scientific advances in the field of genomics have made it possible to more accurately determine the aggressiveness of prostate cancer.

No two prostate cancers are alike. The aggressiveness of your prostate cancer is linked to the activity of certain genes in your tumor.

The Decipher test measures the activity of those genes to provide a personalized assessment of your risk after surgery.

Your Decipher risk tells you how likely your cancer is to spread beyond your prostate; it provides information that is distinct from that given by traditional measures such as Gleason score or PSA.

**Decipher adds a unique piece of information to allow you and your doctor to make more informed decisions about your post-operative care.**
Decipher® helps you and your doctor make more informed decisions about your next steps after surgery.

Your doctor uses your surgery specimen and PSA to determine your clinical risk of metastasis, or disease recurrence.
Decipher adds new information about the aggressiveness of your cancer by assessing your genomic risk

- Provides a more accurate and independent assessment than clinical risk alone

- Assesses the activity of genes determined to be associated with aggressive prostate cancer

- Based on the biology of your tumor, predicts your risk of metastasis after surgery
Your Decipher test result is reported as a probability of metastasis associated with a risk category of low, average or high risk.

• Based on clinical studies that evaluate patient outcomes, Decipher associates that genomic risk with a risk category:

**Low Risk**

98% of men in this category were metastasis free at 5 years. In studies, 60% of clinically high-risk men tested fell into this category.

**Average Risk**

The average risk of developing metastasis across all high risk men studied

**High Risk**

On average, 1 in 5 men in this category experienced metastasis within 5 years of surgery
If your Decipher risk is low, your doctor may decide that you are a good candidate for active monitoring with regular PSA checks. This means your doctor will closely follow you and watch for any changes.

If your Decipher risk is average, that means your risk is in line with the average of high risk men tested in clinical studies.

If your Decipher risk is high, your doctor may decide that you are an appropriate candidate for additional treatment. Men experienced lower rates of metastasis when additional treatment was administered, post-surgery.²
Understand your payment options

Medicare coverage for patients post-surgery with pT3 staging, positive margins, and/or rise in PSA.

All private insurance plans accepted.

Proven and comprehensive financial assistance through the GenomeDx Patient Care Program.

To learn more about Decipher® visit www.deciphertest.com or contact the GenomeDx Patient Care Team today at 1.888.792.1601 (toll free)

References


The information contained in this educational guide is provided by GenomeDx Biosciences Inc. and is not intended to be a substitute for information provided by a practicing physician. Talk to your doctor about the information you are considering before you decide on the course of treatment that is best for you.

Copyright © 2015 GenomeDx Biosciences Inc.